| 37.91 -1.28 (-3.27%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 46.4 |
1-year : | 54.2 |
| Resists | First : | 39.72 |
Second : | 46.4 |
| Pivot price | 37.21 |
|||
| Supports | First : | 36.2 |
Second : | 34.02 |
| MAs | MA(5) : | 38.56 |
MA(20) : | 37.16 |
| MA(100) : | 37.35 |
MA(250) : | 31.13 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 80.3 |
D(3) : | 83.4 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 46.47 | Low : | 16.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TGTX ] has closed below upper band by 35.4%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 39.59 - 39.79 | 39.79 - 39.97 |
| Low: | 37.19 - 37.42 | 37.42 - 37.61 |
| Close: | 37.53 - 37.92 | 37.92 - 38.25 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Fri, 11 Jul 2025
A Note On TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE and Debt To Equity - simplywall.st
Sat, 28 Jun 2025
TG Therapeutics: Strong Execution Tempered By An Evolving Market (NASDAQ:TGTX) - Seeking Alpha
Wed, 25 Jun 2025
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel (NASDAQ:TGTX) - Seeking Alpha
Thu, 19 Jun 2025
Have Insiders Sold TG Therapeutics Shares Recently? - simplywall.st
Wed, 28 May 2025
TG Therapeutics: Estimates Could Soon Be Raised Again (NASDAQ:TGTX) - Seeking Alpha
Tue, 06 May 2025
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 159 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 9.7 (%) |
| Held by Institutions | 63.2 (%) |
| Shares Short | 23,700 (K) |
| Shares Short P.Month | 22,570 (K) |
| EPS | 0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 10.1 % |
| Operating Margin | 7.1 % |
| Return on Assets (ttm) | 7.2 % |
| Return on Equity (ttm) | 19.7 % |
| Qtrly Rev. Growth | 90.4 % |
| Gross Profit (p.s.) | 2.12 |
| Sales Per Share | 2.43 |
| EBITDA (p.s.) | 0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | 151.63 |
| PEG Ratio | 0 |
| Price to Book value | 23.25 |
| Price to Sales | 15.57 |
| Price to Cash Flow | -98.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|